Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Research & Development (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Research & Development for 13 consecutive years, with $46.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 11.75% year-over-year to $46.1 million, compared with a TTM value of $193.1 million through Dec 2025, down 2.9%, and an annual FY2025 reading of $193.1 million, down 2.9% over the prior year.
  • Research & Development was $46.1 million for Q4 2025 at Tandem Diabetes Care, down from $48.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $52.2 million in Q4 2024 and bottomed at $18.0 million in Q1 2021.
  • Average Research & Development over 5 years is $39.6 million, with a median of $42.4 million recorded in 2023.
  • The sharpest move saw Research & Development surged 84.62% in 2022, then dropped 11.75% in 2025.
  • Year by year, Research & Development stood at $29.5 million in 2021, then increased by 20.66% to $35.6 million in 2022, then grew by 19.72% to $42.6 million in 2023, then increased by 22.52% to $52.2 million in 2024, then decreased by 11.75% to $46.1 million in 2025.
  • Business Quant data shows Research & Development for TNDM at $46.1 million in Q4 2025, $48.7 million in Q3 2025, and $48.1 million in Q2 2025.